Media
AAHI pioneers immune-enhancing platforms to provide potent, durable, broadly effective, and efficient vaccines and immunotherapies that are accessible to those who most need them.
AAHI in the News
Filter by year
The Covid Gambit: Pfizer, Moderna Struggle to Get The Jump On Covid
BaiyaPhytopharm Announces Preliminary Results of the Phase 1 Clinical Trial of its COVID-19 Vaccine Baiya SARS-CoV-2 Vax 2
AAHI Contributes Its Unique Adjuvant Formulation Profiles to the National Institute of Health's Vaccine Adjuvant Compendium
Global Institute Simplifies Vaccine Manufacturing for Developing World
Two-Step QS-21 Purification Simplifies Process for Greater Use
More Durable, Broader Spectrum Boosters Needed Against COVID-19
From the fringes to the forefront - the mRNA era has taken hold of pharma
Pan-coronavirus vaccine pipeline takes form
The Access To Advanced Health Institute Receives $26 Million Donation from the Chan Soon-Shiong Family Foundation to Further Develop Immune-Enhancing Platform Technology
Released from court oversight, a Seattle research institution rebrands and resets
Infectious Disease Research Institute Exits Receivership and Launches AAHI, the Access to Advanced Health Institute, with $50 Million Funding Commitment
Featured Publication
A flexible, thermostable nanostructured lipid carrier platform for RNA vaccine delivery
Current RNA vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are limited by instability of both the RNA and the lipid nanoparticle delivery system, requiring storage at −20°C or −70°C and compromising universally accessible vaccine distribution. This study demonstrates the thermostability and adaptability of a nanostructured lipid carrier (NLC) delivery system for RNA vaccines that has the potential to address these concerns. Liquid NLC alone is stable at refrigerated temperatures for ≥1 year, enabling stockpiling and rapid deployment by point-of-care mixing with any vaccine RNA. Alternatively, NLC complexed with RNA may be readily lyophilized and stored at room temperature for ≥8 months or refrigerated temperature for ≥21 months while still retaining the ability to express protein in vivo. The thermostability of this NLC/RNA vaccine delivery platform could significantly improve distribution of current and future pandemic response vaccines, particularly in low-resource settings.
Read More